Free Trial
John Sourbeer

John Sourbeer Analyst Performance

Executive Director at UBS Group

John Sourbeer is a stock analyst at UBS Group, covering 6 publicly traded companies across a range of sectors. Over the past year, John Sourbeer has issued 6 stock ratings, including buy and hold recommendations. While full access to John Sourbeer's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights John Sourbeer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
7 Last 3 Years
Buy Recommendations
57.14% 4 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy57.1%4 ratings
Hold42.9%3 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by John Sourbeer at UBS Group, the majority (57.1%) have been Buy recommendations, followed by 42.9% Hold.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
3 companies
NASDAQ
50.0% of companies on NASDAQ
3 companies

John Sourbeer, an analyst at UBS Group, currently covers 6 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
5 companies
83.3%
Transportation
1 company
16.7%

John Sourbeer of UBS Group specializes in stock coverage within the Medical sector, with additional focus on Transportation companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
1 company
16.7%
MEDICAL SERVICES
1 company
16.7%
MED/DENTAL - SUPP
1 company
16.7%
TRANS - SERVICES
1 company
16.7%
MED - DRUGS
1 company
16.7%
ANALYTICAL INSTRUMENTS
1 company
16.7%

John Sourbeer's Ratings History at UBS Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Qiagen N.V. stock logo
QGEN
Qiagen
8/7/2025Boost Price Target$47.96$50.00Neutral
Icon Plc stock logo
ICLR
Icon
7/25/2025Boost Price Target$185.58$240.00Buy
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
7/25/2025Boost Price Target$268.25$320.00Buy
CryoPort, Inc. stock logo
CYRX
CryoPort
3/24/2025Upgrade$5.69$10.00Buy
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
3/7/2025Lower Price Target$21.16$23.50Neutral
Qiagen N.V. stock logo
QGEN
Qiagen
2/7/2025Lower Price Target$40.93$48.00Neutral